Stage (next event)
Catalyst Info & Data Links
TITLE: Neratinib for Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov (NCT01953926): Neratinib HER Mutation Basket Study (SUMMIT)
WHAT IS THE CATALYST EVENT?
Phase 2 Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
H1 2021 (see slide 45)
Mechanism of Action
MECHANISM OF ACTION
Neratinib is an intracellular kinase inhibitor that irreversibly binds to epidermal growth factor receptor (EGFR), HER2, and HER4. In vitro, neratinib reduces EGFR and HER2 autophosphorylation, downstream MAPK and AKT signaling pathways, and showed antitumor activity in EGFR and/or HER2 expressing carcinoma cell lines. Neratinib human metabolites M3, M6, M7 and M11 inhibited the activity of EGFR, HER2, and HER4 in vitro. In vivo, oral administration of neratinib inhibited tumor growth in mouse xenograft models with tumor cell lines expressing HER2 and EGFR.
~228,820 adults (116,300 men and 112,520 women) in the United States will be diagnosed with lung cancer.
Learn more at Cancer.net
Updated by HC
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post